LVCLY Living Cell Technologies Ltd. Sponsored ADRs
Living Cell Technologies Limited, a biotechnology company, discovers, develops, and commercializes regenerative treatments that use naturally occurring cells to restore functions in New Zealand. The company's lead product is NTCELL, an alginate coated capsule, which is in clinical trials for the treatment of Parkinson's disease. Living Cell Technologies Limited has a research collaboration agreement with the Centre for Brain Research at the University of Auckland to identify and synthesize a pericyte protective agent for treatment of neurodegenerative disease. The company was founded in 1987 and is based in Melbourne, Australia. This is an ADR of a company whose stock trades outside of the U.S. as the symbol AT:LCT.
This security is traded over-the-counter, or OTC. We don't always have accurate pricing data on OTC stocks.
$0.06 OTCQB
As of 03/23/2023 OTCMarkets
Security Information
Category1: US Equity
Category2: ADRs
Category3: Micro cap
GICS sector: Health Care
Industry: Biotechnology
Index country: Australia
Country of incorporation: Australia
IPO date: 07/17/2007
Outstanding shares: 138,536,372
Average volume: 2,146
Market cap: $7,758,037
Current dividend yield: 0.00%
Sedol:
Valuation (See tab for details)
PE ratio: 0.00
PB ratio: 0.00
PS ratio: 0.00
Return on equity: 0.00%
Net income %: 0.00%